The estimated Net Worth of Manuel O. Mendez is at least $78.8 Milion dollars as of 24 June 2022. Mr. Mendez owns over 66,666 units of Quest Diagnostics stock worth over $74,220,615 and over the last 15 years he sold DGX stock worth over $0. In addition, he makes $4,583,110 as Executive Officer at Quest Diagnostics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Mendez DGX stock SEC Form 4 insiders trading
Manuel has made over 2 trades of the Quest Diagnostics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 66,666 units of DGX stock worth $20,000 on 24 June 2022.
The largest trade he's ever made was exercising 416,667 units of Quest Diagnostics stock on 1 April 2022 worth over $63,983,385. On average, Manuel trades about 48,333 units every 8 days since 2009. As of 24 June 2022 he still owns at least 483,333 units of Quest Diagnostics stock.
You can see the complete history of Mr. Mendez stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Manuel Mendez biography
Manuel O. Mendez serves as Executive Officer of the Company. Manuel joins Quest from QIAGEN N.V., a worldwide provider of Sample to Insight solutions for molecular testing, where he helped accelerate growth and led a global commercial team as SVP, Head of Global Operations and member of the Executive Committee. Before joining QIAGEN in 2014, he served as EVP Americas for bioMérieux from 2010-2014. Manuel has held a variety of sales, marketing and general management roles with Abbott Laboratories, Thermo Fisher Scientific and OraSure Technologies - with leadership positions in the United States , Latin America , Europe and Asian markets. Manuel received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University . He is fluent in Spanish and has served on several boards, including 908 Devices, a maker of point-of-need chemical analyzers; Village Care of New York ; and the Jorge Posada Foundation.
What is the salary of Manuel Mendez?
As the Executive Officer of Quest Diagnostics, the total compensation of Manuel Mendez at Quest Diagnostics is $4,583,110. There are 1 executives at Quest Diagnostics getting paid more, with Stephen Rusckowski having the highest compensation of $10,118,500.
How old is Manuel Mendez?
Manuel Mendez is 52, he's been the Executive Officer of Quest Diagnostics since 2019. There are 19 older and 2 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
What's Manuel Mendez's mailing address?
Manuel's mailing address filed with the SEC is C/O QUOTIENT LIMITED, BUSINESS PARK, TERRE BONNE, ROUTE DE CRASSIER 13, EYSINS, V8, 1262.
Insiders trading at Quest Diagnostics
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty oraz Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
What does Quest Diagnostics do?
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
What does Quest Diagnostics's logo look like?
Complete history of Mr. Mendez stock trades at Orasure Technologies, Quotient Ltd oraz Quest Diagnostics
Quest Diagnostics executives and stock owners
Quest Diagnostics executives and other stock owners filed with the SEC include:
-
Stephen Rusckowski,
Chairman of the Board, President, Chief Executive Officer -
Manuel Mendez,
Executive Officer -
Stephen H. Rusckowski,
Chairman, Pres & CEO -
Mark Guinan,
Chief Financial Officer, Executive Vice President -
James Davis,
Executive Vice President, General Diagnostics -
Carrie Manner,
Senior Vice President - Advanced Diagnostics -
Catherine Doherty,
Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing -
Michael Prevoznik,
Senior Vice President, General Counsel -
James E. Davis,
Exec. VP of Gen. Diagnostics -
Carrie Eglinton Manner,
Sr. VP of Advanced Diagnostics -
Daniel Stanzione,
Lead Independent Director -
Gary Pfeiffer,
Independent Director -
Denise Morrison,
Independent Director -
Gail Wilensky,
Independent Director -
Timothy Main,
Independent Director -
Timothy Ring,
Independent Director -
Vicky Gregg,
Independent Director -
Helen Torley,
Independent Director -
Wright Lassiter,
Independent Director -
Michael E. Prevoznik,
Sr. VP & Gen. Counsel -
Mark J. Guinan,
Exec. VP & CFO -
Gary D. Samuels,
VP of Corp. Communications -
Timothy Sharpe,
VP of Compliance -
Shawn C. Bevec,
VP of Investor Relation -
Gabrielle Wolfson,
Sr. VP and Chief Information & Digital Officer -
Michael J. Deppe,
VP, Corp. Controller & Chief Accounting Officer -
Robert B Carter,
Director -
Jeffrey M Leiden,
Director -
Jenne K Britell,
Director -
Robert A Klug,
VP, Corporate Controller -
Everett Cunningham,
SVP, Commercial -
John B Ziegler,
Director -
Jon R Cohen,
SVP and Chief Medical Officer -
William F Buehler,
Director -
John B. Haydon,
SVP, Operations -
Kathy Ordonez,
SVP, Discovery & Development -
Robert Hagemann,
Corp VP & Chief Fin Officer -
Surya N Mohapatra,
President & COO -
Joan Elizabeth Miller,
Sr VP -Pathology& HospServices -
John C Md Baldwin,
Director -
Wayne R. Simmons,
Vice President, Operations -
Rosanne Haggerty,
Director -
Plc Gsk,
10% owner -
Thomas W Ii Grant,
Executive Officers -
William R Grant,
Director -
Thomas F Bongiorno,
Vice President and Controller -
James F Iii Flaherty,
Director -
David M Zewe,
Sr. VP -Diagnostic Testg Ops -
Robert E Peters,
Vice President, Sales & Mktg. -
Kenneth W/Nj Freeman,
Chairman, Chief Exec Officer -
Mary A Cirillo,
Director -
Kenneth D Brody,
Director -
Gerald C Marrone,
Sr. VP, Administration -
Luis Diaz,
Director -
Tracey Doi,
Director -
Michael J Deppe,
SVP, Corp. Controller & CAO -
Sam Samad,
Executive Vice President & CFO -
Patrick Plewman,
SVP for Diagnostic Services -
Karthik Kuppusamy,
SVP, Clinical Solutions -
J. E. Davis,
CEO and President -
Mark E Delaney,
SVP & Chief Commercial Officer -
Mark A Gardner,
SVP of Molecular Gen & Oncol